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ARTICLE
Lornoxicam use to reduce the pain associated with propofol injection
Nihal Başaka, Yakup Aksoy b, Ayhan Kaydu a and Ömer Fatih Şahin b
aSelahaddin Eyyübi State Hospital, Diyarbakır, Turkey; bDepartment of Anesthesiology, Bismil State Hospital, Diyarbakır, Turkey
ABSTRACT
Aim: To investigate the efficacy of lornoxicam in the prevention of the pain associated with
propofol injection.
Material and method: Approval for this study was granted by the ethics committee of our
hospital. Using a computer randomisation software, 120 patients undergoing elective surgery
were assigned to four equal groups. In Group I (control group), immediately before anaes-
thesia induction, 10 ml of isotonic 0.9% NaCl solution (placebo) was administered intrave-
nously (IV). In Groups II, III and IV, the same injection contained 2 mg, 4 mg and 8 mg of
lornoxicam respectively. A tourniquet was then applied to the forearm for two minutes. Pain
evaluation was made using a verbal pain score.
Results: Differences in pain severity scores were statistically significant between Groups I and
II, Groups I and III, Groups I and IV and between Groups II and III (p < 0.05). However, no
significant difference was determined between Groups III and IV (p = 0.401).
Conclusion: In all groups administered with lornoxicam, there was a significant reduction in
the severity of pain associated with propofol injection, in comparison with the control group.
Maximum effect is obtained with a dose of 4 mg.
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Propofol (2,6-diisopropylphenol), a widely used intra-
venous (IV) anaesthetic, was developed in the 1970s
from phenol derivatives [1,2]. Just as propofol is used
for the induction and maintenance of anaesthesia, it
is also often used outside operating theatres for
sedation. As propofol has a rapid onset time and
early recovery, it is close to ideal as an anaesthetic
agent [3,4]. The most frequently seen side-effect of
its use is injection pain and associated patient dis-
comfort [5]. The incidence of pain and discomfort
during propofol injection has been reported at
rates between 28% and 90% [6]. Many methods
have been used to reduce this pain including the
addition of lidocaine to propofol, adjusting the pH of
the propofol emulsion, prior administration of alfen-
tanil, remifentanil, ketamine, metoclopramide, nafa-
mostat, granisetron, oral clonidine, cold saline
solution, ketorolac, thiopental, magnesium sulfate,
ephedrine, or the topical application of nitroglycer-
ine, EMLA, or 60% lidocaine band [7–15].
Although the mechanism of the pain which occurs
during propofol injection has not been fully clarified,
there are known to be several factors which have an
effect. These are the administration of the injection to
veins in the dorsal area of the hand, the temperature
of the propofol formulation, the rate of administration
of the drug, aqueous phase propofol concentration,
the buffering effect of the blood and administration
together with agents such as opioids and local anaes-
thetics [16].
Lornoxicam (aka chlorotenoxicam) is a non-steroid
anti-inflammatory drug (NSAID) of the oxicam family.
It is available in oral and parenteral forms. Unlike
other known oxicams, elimination half life of lornox-
icam is relatively short (circa four hours), which is
advantageous with respect to tolerability [17].
Although the mechanism responsible for the pain
associated with propofol injection is not fully known, it
is, however, thought to involve the activation of the
kinin cascade system and other pain mediators. Our
hypothesis is that the anti-inflammatory properties of
lornoxicam can reduce propofol injection pain.
Consequently, we undertook the present study to eval-
uate the efficacy of lornoxicam in the prevention of
propofol pain. To the best of our knowledge, there
have been no prior studies in the literature addressing
this topic. The aim of the present study was to investi-
gate the role and effective dose of lornoxicam in pre-
venting the pain associated with the intravenous
injection of propofol.
Material and Method
Approval for the study was granted by the Ethics
Committee of Dicle University Medical Faculty. The
study included a total of 120 patients, aged
18–65 years, of ASA I-II, who were to undergo elective
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surgery. The patients had no contraindications for
general anaesthesia and had no allergic reactions to
the drugs to be used. Written informed consent was
obtained from all the patients. Exclusion criteria were
pregnancy, extensive heart and circulatory system
impairment, respiratory tract disease, neurological dis-
eases, liver and kidney function impairments, bleed-
ing and clotting problems, a history of gastrointestinal
ulcer or non-acceptance of the procedure.
Using a computer-generated randomisation pro-
gram, the patients were allocated to one of four
groups of 30 patients each. Immediately before
anaesthesia induction, a syringe injector of 10 ml
equivalent was prepared for each patient. The syr-
inge injectors were prepared for Group I (control)
with 10 ml isotonic 0.9% NaCl solution. For Groups
II, III and IV, the same solution contained 2 mg, 4
mg and 8 mg of lornoxicam (Xefo, Abdi Ibrahim,
Turkey) respectively. The assistant preparing the
drugs wrote the group number on the outside of
each syringe injector. Then the drug amount, col-
our and group number were covered with a plaster
so as not to be visible and the syringe injector was
given to another assistant in the operating theatre
who was blinded to the study groups.
Routine monitoring was applied to all patients in
the operating theatre with 3-channel electrocardio-
graphy (ECG), peripheral oxygen saturation (SpO2)
and noninvasive arterial pressure monitorisation
(Nihon Kohden/Japan). No premedication was applied
to the patients. A 20-gauge intravenous cannula was
placed in the dorsal area of the hand. Also, an infusion
of a Ringer Lactate solution (Na+: 130 mEq/L, K+: 4
mEq/L, Cl: 109 mEq/L, lactate: 28 mEq/L) was started
at the rate of 100 ml/hour.
To achieve a double-blind study, the syringe injectors
were prepared and their contents were masked before
an assistant took them to another in the operating
theatre. For each patient, the syringe injector to be
used was selected at random. To prevent serum circula-
tion in the forearm, a tourniquet was applied for 2 min-
utes. A 2mg/kg dose of propofol was calculated for each
patient for anaesthesia induction in all groups. The drug
(10 mg/ml ampoule) was supplied by Fresenius com-
pany (Bursa/Ankara, Turkey). In the operating room, first
25% of the calculated dose was injected over 10 sec-
onds. Pain was evaluated by a different anaesthetist
within the following 20 seconds, then the remainder of
the propofol dose was given, and induction of anesthe-
sia continued.
Pain was evaluated by asking the patient to score the
pain felt according to the following scale: 0 = no pain,
1 = mild, 2 = moderate, 3 = severe, as shown in Table 1.
After completion of the IV anaesthesia agent injection,
0.15 mg/kg vecuronium (Norcuron 2 mg/ml, Organon,
Turkey) was used for oral intubation. Following intuba-
tion, 1 mcg/kg fentanyl (50 mcg/ml Fentanyl Citrate,
Abbott, Turkey) was added. The surgical procedure
was then started. Throughout the operation, patients
were monitored with ECG, systemic blood pressure and
SpO2 values. Systemic blood pressure was measured
with the non-invasive oscillometric method.
After completing the pain evaluation, the plaster
covering the details on the syringe injector was
removed by another assistant and the group number
written on the syringe injector was recorded on the
prepared form, together with the patient demo-
graphic data and pain scores. All patients were fol-
lowed up for 24 hours for pain, oedema, inflammation
and allergic reactions which might have developed in
the injection site.
Power analysis in the current study was calculated on
the assumptions that the incidence of pain associated
with the propofol injection without pre-medication
would be 65%, and with premedication 35% [5]. Based
on these assumptions, a total of 48 subjects was neces-
sary to determine a significant difference at 80% power
per group (one-way, α = 0.05). The current study was
planned with a total of 120 subjects – 30 cases per
group. Continuous and categorical data were analysed
using the one-way ANOVA and Chi-square tests.
Statistical analysis of the data was made using SPSS for
Windows v. 13.0 software (Statistical Package for Social
Sciences SPSS Inc. Chicago, IL, USA). Differences
between the groups in the severity of pain were eval-
uated using the Chi-square test. The Mann Whitney
U-test and the Kruskal Wallis tests were applied. A
value of p < 0.05 was accepted as statistically significant.
Results
The study included a total of 120 patients randomly
allocated to four equal groups of 30. The demo-
graphic data such as age, sex, body weight and addi-
tional features were evaluated in each group. No
statistically significant difference was determined
between the groups in respect of demographic data.
Due to the randomisation system, the groups were
not homogenous and a statistically significant differ-
ence was observed between the groups in respect of
Table 1. Verbal pain scale.
No pain Mild pain Moderate pain Severe pain
(The patient stated that they felt pain or burning,without
a behavioural response and without grimacing)
(The patient stated pain or burning with a
grimace; the pain was reported without
asking)
(The patient withdrew their
arm with pain and crying)
0 1 2 3





























the number of males and females (p < 0.05). There
were more females in Groups I and II, while in Groups
III and IV the numbers of males and females were
comparable (Table 2).
To determine an effective dose of lornoxicam,
doses of 2 mg, 4 mg, and 8 mg were compared with
the control group. Pain associated with propofol injec-
tion was seen at 93.3% in the control group and the
overall incidence of pain was 83.3% (Table 3). No
difference was observed in the incidence of pain
between Group I (control) and Group II (2 mg). In
Group III (4 mg), a significant reduction in pain was
observed (p = 0.015). While the incidence of pain in
Group II (2 mg) was not significantly different from
that observed in the control group (Table 3), none of
the patients in Group II experienced severe pain
(Tables 4).
When the severity of pain during propofol injec-
tion was evaluated, a statistically significant reduc-
tion in the severity of pain was seen between
Groups I and II (p = 0.0002), between Groups I
and III (p = 0.0001), between Groups I and IV
(p = 0.00001) and between Groups II and III
(p = 0.026). No statistically significant difference
was determined in the severity of pain between
Groups III and IV (p = 0.401) (Table 4).
statistically significant difference in the severity of
pain was observed in all the lornoxicam groups
compared with the control group. Pretreatment
with 4 mg of lornoxicam was as effective in the
reduction of propofol pain as the pretreatment with
8 mg. While pretreatment with 2 mg lornoxicam did
not affect the incidence of propofol pain, it signifi-
cantly reduced its severity compared to the control
group. The use of 4 mg and 8 mg lornoxicam was
found to be effective in the reduction of both the
incidence and severity of the pain associated with
propofol injection. When the severity of pain during
propofol injection was evaluated according to sex,
no statistically significant differences were found
between the groups (Table 4).
Discussion
In this study which investigated the efficacy of lornox-
icam in the prevention of pain which occurs as a
result of propofol injection, it was concluded that
lornoxicam reduced the severity of pain in all the
groups. The mechanism of propofol injection pain
involves the release of kinins as a result of direct
irritation of vascular endothelium (especially tunica
media and intima) by propofol. Propofol frees brady-
kinin by activating the kinin-kallikrein system, and
thereby causing venous dilation and hyperpermeabil-
ity. This creates pain by creating greater contact of
propofol with free nerve ends. Slow administration of
the injection causes greater pain by removing the
interaction of the propofol active component with
the endothelium [18]. The effect of lornoxicam is
based on the inhibition of the synthesis of
Table 2. Demographic data.
Group I Group II Group III Group IV
p value(n = 30) (n = 30) (n = 30) (n = 30)
Age (mean±1SD1), years 29.8 ± 9.6 29.6 ± 8.5 35.2 ± 11.0 30.2 ± 8.6 0.075
Sex, n
Male 9 (30%) 9 (30%) 15 (50%) 14 (46%) 0.043
Female 21 (70%) 21 (70%) 15 (50%) 16 (54%)
Body weight (mean±1SD), kg 65.5 ± 9.2 63.8 ± 11.3 70.8 ± 11.9 67.3 ± 11.1 0.087
ASA, n2
I 13 (43%) 18 (60%) 8 (27%) 14 (46%)
II 17 (57%) 12 (40%) 22 (73%) 16 (54%)
Additional features, n
DM3 2 0 4 1
HT4 3 3 1 2
Smoking 19 16 21 20
Results given as mean ± standard deviation (SD). In the comparison of age, sex, bodyweight, the one-way ANOVA test was used.
1SD: Standard deviation; 2ASA: American Society of Anesthesiologists; 3DM: Diabetes Mellitus; 4HT: Hypertension
Table 3. Pain incidence during propofol injection.
Pain (−) Pain (+)
Group I (n = 30) 2 (6.7%) 28 (93.3%)
Group II (n = 30) 2 (6.7%) 28 (93.3%)
Group III (n = 30) 10 (33.3%) 20 (66.7%)
Group IV (n = 30) 6 (20%) 24 (80%)
Total (n = 120) 20 (16.7%) 100 (83.3%)
Table 4. Distribution of the severity of pain during propofol
injection and according to sex.








2 (6.7%) 7 (23.3%) 7 (23.3%) 14 (46.6%)
Group II
(n = 30)
2 (6.7%) 18 (60%) 10 (33.3%) None
Group III
(n = 30)
10 (33.3%) 15 (50%) 4 (13.3%) 1 (3.3%)
Group IV
(n = 30)




10 (13.7%) 34 (46.6%) 19 (26.0%) 10 (13.7%)
Male
(n = 47)
10 (21.3%) 26 (55.3%) 5 (10.6%) 6 (12.8%)
Total
(n = 120)
20 (16.7%) 60 (50%) 24 (20%) 16 (13.3%)





























prostaglandins (PGs), which are mediators of inflam-
mation [19]. The selection of lornoxicam in the pre-
sent study was based on the PG inhibition potential of
an NSAID resulting in the inhibition of the kinin
cascade.
Various drugs andmethods have been used to reduce
the incidence or the severity of propofol injection pain.
The most effective method has been reported to be the
injection of 0.5 mg/kg lidocaine, which causes venous
occlusion, before the administration of propofol [19]. In
a study by Liley et al., the addition of lidocaine to the
propofol emulsion was shown to reduce pain incidence
by destabilising the emulsion [20]. In another studywhich
compared lidocaine, saline andmetoprolol in the preven-
tion of propofol pain, metoprolol was found to be as
effective as lidocaine [16].
Niazi et al. [21] reported that the total injection
given at a rate of 10–20 seconds could reduce or
delay pain. In the current study, the propofol injection
was calculated to be given at the rate of 10 seconds.
The slow IV injection was set to give 25% of the total
dose in 10 seconds and the patient was questioned
about the incidence of pain 20 seconds after the
injection. The purpose of adjusting the rate in this
way was to be able to evaluate the pain effect of
delayed propofol effect. This is because the indirect
effect of kinin activation caused by the direct irritant
effect of propofol is thought to be responsible for
injection pain [22].
In a study by Canbay et al. [23] using acetamino-
phen, which is an anilide group analgesic, the pain
incidence was seen to be 64% in the control group,
22% in the acetaminophen group and 8% in the
lidocaine group. It was concluded that pretreatment
with 50 mg IV acetaminophen was determined to be
effective in reducing propofol injection pain. NSAIDs
have also been used previously as pretreatment for
propofol injection pain. Fujii et al. [24] determined
pain incidence as 90% in a control group and
reported that pretreatment with 50 mg and 75 mg
flurbiprofen axetil was effective in the reduction of
severity and prevention of propofol injection pain.
In our study, lornoxicam was used as NSAID and
comparison with the control group was made of
doses of 2 mg, 4 mg and 8 mg. Canbay et al. [23]
compared a single dose of acetaminophen with lido-
caine and a control group. In the present study, we
observed a 93% incidence of pain in the control
group. Our results indicate that pretreatment with
4 mg or 8 mg lornoxicam is effective in reducing
both the incidence and the severity of the pain asso-
ciated with propofol injection.
To the best of our knowledge, there is no study in
the literature which has investigated lornoxicam pre-
treatment for reducing propofol pain. There is a need
for further studies to compare this efficacy with other
pretreatments, especially lidocaine. In the present
study we found no statistically significant difference
between males and females with respect to incidence
or severity of propofol pain. However, because gender
distribution in our study was uneven, no definitive
conclusions can be made with respect to incidence
and severity of pain in males vs females.
Conclusion
Pretreatment with 4 mg and 8 mg of lornoxicam is
effective in reducing both the incidence and the
severity of the pain associated with propofol injection.
Maximum effect is obtained with dose of 4 mg.
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